Report Sections

See All Reports

  • HP:0002015: Dysphagia
  • Pneumonia (312) Abnormality of the cardiovascular system (29) Neoplasm (27) Respiratory tract infection (27) Hypoxemia (22) Depressivity (21) Diabetes mellitus (19) Acute kidney injury (19) Abnormal lung morphology (19) Thromboembolism (17) Hypertension (16) Anosmia (14) Myocardial infarction (14) Abnormality of coagulation (14) Stroke (13) Pulmonary embolism (13) Arthritis (12) Leukemia (12) Interstitial pneumonitis (12) Autistic behavior (11) Mental deterioration (11) Deep venous thrombosis (10) Type II diabetes mellitus (10) Pulmonary obstruction (10) Crohn's disease (10) Abnormality of the kidney (9) Autism (9) Obesity (9) Congestive heart failure (9) Chronic pulmonary obstruction (9) Chronic pain (9) Rheumatoid arthritis (8) Abnormality of the liver (8) Respiratory distress (8) Pulmonary fibrosis (8) Colitis (8) Myocarditis (8) Carcinoma (8) Ulcerative colitis (8) Behavioral abnormality (7) Dementia (7) Infertility (7) Inflammation of the large intestine (7) Pulmonary insufficiency (7) Low levels of vitamin D (7) Neoplasm of the lung (7) Type I diabetes mellitus (7) Psychosis (6) Coronary artery atherosclerosis (6) Lymphoma (6) Abnormality of the gastrointestinal tract (6) Chronic kidney disease (6) Sepsis (6) Renal insufficiency (5) Lymphopenia (5) Gastroparesis (5) Immunodeficiency (5) Systemic lupus erythematosus (5) Breast carcinoma (5) Peripheral arterial stenosis (5) Allergy (5) Encephalopathy (4) Hepatic fibrosis (4) Cardiac arrest (4) Dysphagia (4) Asthma (4) Alzheimer disease (4) Osteoarthritis (4) Neoplasm of the pancreas (4) Autoimmunity (4) Disseminated intravascular coagulation (4) Attention deficit hyperactivity disorder (4) Sleep apnea (4) Prostate cancer (4) Neoplasm of head and neck (4) Addictive behavior (4) Insomnia (4) Obsessive-compulsive behavior (3) Seizure (3) Cardiomyopathy (3) Weight loss (3) Fever (3) Migraine (3) Pulmonary arterial hypertension (3) Bronchiectasis (3) Obstructive sleep apnea (3) Colon cancer (3) Reduced factor VIII activity (3) Malnutrition (3) Knee osteoarthritis (3) Lymphoid leukemia (3) Renal cell carcinoma (3) Arrhythmia (3) Fatigue (3) Endometriosis (3) Non-small cell lung carcinoma (3) Neuroendocrine neoplasm (3) Hypercoagulability (3) Schizophrenia (3) Hearing impairment (2) Visual impairment (2) Conjunctivitis (2) Uveitis (2) Agoraphobia (2) Abnormality of the endocrine system (2) Abnormal heart morphology (2) Tachycardia (2) Angina pectoris (2) Gastroesophageal reflux (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Mutism (2) Headache (2) Transient ischemic attack (2) Hyperkinetic movements (2) Polyphagia (2) Atherosclerosis (2) Hypoventilation (2) Myelodysplasia (2) Psoriasiform dermatitis (2) Paroxysmal atrial fibrillation (2) Acute myeloid leukemia (2) Lymphoproliferative disorder (2) Myeloproliferative disorder (2) Multiple myeloma (2) Intervertebral disc degeneration (2) Stridor (2) Cystoid macular edema (2) Hemeralopia (2) Cutaneous melanoma (2) Arteritis (2) Glioblastoma multiforme (2) Cervix cancer (2) Pulmonary edema (2) Ovarian neoplasm (2) Angioedema (2) Mania (2) Neoplasm of the large intestine (2) Urinary retention (1) Urinary incontinence (1) Nephritis (1) Menorrhagia (1) Xerostomia (1) Hypogeusia (1) Conductive hearing impairment (1) Abnormality of the eye (1) Cataract (1) Amblyopia (1) Periodontitis (1) Enuresis (1) Hypoparathyroidism (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Osteopenia (1) Abnormality of the skin (1) Jaundice (1) Lymphedema (1) Angiokeratoma corporis diffusum (1) Keratoconjunctivitis (1) Spasticity (1) Hemiparesis (1) Polyneuropathy (1) Syncope (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic steatosis (1) Hepatic failure (1) Hepatocellular carcinoma (1) Premature birth (1) Sudden cardiac death (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Pancreatitis (1) Abnormality of blood and blood-forming tissues (1) Gout (1) Diarrhea (1) Anorexia (1) Esophageal varix (1) Hypothermia (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Encephalitis (1) Waddling gait (1) Increased intracranial pressure (1) Celiac disease (1) Biliary cirrhosis (1) Hypotension (1) Osteomyelitis (1) Squamous cell carcinoma (1) Central apnea (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Skeletal muscle atrophy (1) Male infertility (1) Spondylolisthesis (1) Myalgia (1) Back pain (1) Low back pain (1) Muscular dystrophy (1) Neonatal death (1) Thrombophlebitis (1) Chronic bronchitis (1) Ventricular tachycardia (1) Coronary artery stenosis (1) Chronic lymphatic leukemia (1) Hypersensitivity pneumonitis (1) Intraalveolar phospholipid accumulation (1) Abnormal anterior horn cell morphology (1) Amyotrophic lateral sclerosis (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Stomatitis (1) Uterine neoplasm (1) Intestinal atresia (1) Inflammatory abnormality of the skin (1) Sinus tachycardia (1) Bronchiolitis (1) Postprandial hyperglycemia (1) Hepatitis (1) Erythroid hypoplasia (1) Hodgkin lymphoma (1) B-cell lymphoma (1) Myeloid leukemia (1) Chronic myelomonocytic leukemia (1) Morphea (1) Bronchitis (1) Hypercapnia (1) Pain (1) Retinal vein occlusion (1) Vasovagal syncope (1) Neonatal asphyxia (1) Dyspareunia (1) Heart murmur (1) Cardiogenic shock (1) Cholangitis (1) Cholangiocarcinoma (1) Small cell lung carcinoma (1) Vulvar neoplasm (1) Neonatal sepsis (1) Glue ear (1) Subdural hemorrhage (1) Endocarditis (1) Toxemia of pregnancy (1) Myositis (1) Vaginal neoplasm (1) Cellulitis (1) Self-injurious behavior (1) Bulimia (1) Neoplasm of the rectum (1) Chest pain (1) Atelectasis (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002015: Dysphagia

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (11)


    Name (Synonyms) Correlation
    drug1312 Fiberoptic Endoscopic Evaluation of Swallowing Wiki 0.71
    drug3959 mechanical ventilator settings and position Wiki 0.50
    drug3968 mindfulness, emotion didactics, interpersonal skills, experiential learning Wiki 0.50
    Name (Synonyms) Correlation
    drug3320 Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST) Wiki 0.50
    drug3973 molecular testing for virus RNA using RT-PCR Wiki 0.50
    drug900 Convalescent Plasma Transfusion Wiki 0.35
    drug1683 Interferon Beta-1A Wiki 0.25
    drug963 DAS181 Wiki 0.20
    drug3309 Survey Wiki 0.13
    drug1745 Ivermectin Wiki 0.11
    drug1520 Hydroxychloroquine Wiki 0.05

    Correlated MeSH Terms (3)


    Name (Synonyms) Correlation
    D003680 Deglutition Disorders NIH 1.00
    D013896 Thoracic Diseases NIH 0.35
    D002318 Cardiovascular Diseases NIH 0.09

    Correlated HPO Terms (1)


    Name (Synonyms) Correlation
    HP:0001626 Abnormality of the cardiovascular system HPO 0.09

    Clinical Trials

    Navigate: Correlations   HPO

    There are 4 clinical trials


    1 Oropharyngeal Dysphagia and Malnutrition in Patients Infected by SARS-CoV-2: Prevalence and Needs of Compensatory Treatment and Follow up in Patients Admitted by COVID-19 at the Consorci Sanitari Del Maresme

    Background: Oropharyngeal dysphagia (OD) is a common complication in/post ICU patients that have been with intubation/mechanical ventilation or with tracheotomies or NG tubes, in patients with acute respiratory infection/pneumonia/respiratory insufficiency with a severe disease needing high concentration of oxygen or noninvasive mechanical ventilation and also in patients discharged from acute hospitals to rehabilitation centers, nursing homes or other facilities. All these situations are common for COVID-19 patients that are currently filling our hospitals due to the pandemic expansion of SARS-CoV-2. OD is associated to prolonged hospitalization, dehydration and severe nutritional and respiratory complications -aspiration pneumonia-, hospital readmissions and mortality. Aim: to assess the prevalence of OD and nutritional risk in these patients and to know their needs of compensatory treatment following the application of an early intervention, and to assess whether OD and malnutrition are indicators of poor prognosis for COVID-19 patients. Methods: prospective study in which we will use the volume-viscosity swallowing test (V-VST) to assess the prevalence of OD, and NRS2002 to assess the nutritional risk in admitted patients with confirmed COVID-19 at the Consorci Sanitari del Maresme, Catalonia, Spain. We will register also results of the EAT-10, nutritional status, the needs of compensatory treatments of these patients following an early intervention with fluid and nutritional adaptation and use of nutritional supplements. We will also collect other clinical variables from medical history of the patient related to hospitalization and we will follow the clinical complications and nutritional status at 3 and 6 months follow up.

    NCT04346212
    Conditions
    1. Oropharyngeal Dysphagia
    2. COVID-19
    3. Sars-CoV2
    4. Nutrition
    Interventions
    1. Diagnostic Test: Swallowing evaluation with the EAT-10 and the volume-viscosity swallowing test (V-VST)
    MeSH:Deglutition Disorders
    HPO:Dysphagia Oral-pharyngeal dysphagia

    Primary Outcomes

    Description: Changes in the prevalence of oropharyngeal dysphagia according to a clinical assessment tool, the Volume-Viscosity Swallowing Test (V-VST).

    Measure: Changes in the prevalence of oropharyngeal dysphagia

    Time: From April to December 2020. And at 3 and 6 months follow-up.

    Secondary Outcomes

    Description: Changes in the eating assessment tool (EAT-10 score). A tool that goes from 0 to 40 points and indicates that the patient is at risk of oropharyngeal dysphagia if he/she presents 3 or more points

    Measure: Changes in the swallowing screening

    Time: From April to December 2020. And at 3 and 6 months follow-up.

    Description: Changes in the percentage of patients with impairements in efficacy and/or safety of swallow.

    Measure: Changes in the swallowing status

    Time: From April to December 2020. And at 3 and 6 months follow-up.

    Description: Changes in the nutritional status of study patients (% malnourished, at risk of malnutrition or wellnourished).

    Measure: Changes in the nutritonal status of study patient's.

    Time: From April to December 2020. And at 3 and 6 months follow-up.

    Description: Changes in the fluid (volume and viscosity) requirements of study patients.

    Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (fluid adaptation).

    Time: From April to December 2020. And at 3 and 6 months follow-up.

    Description: Changes in the nutritional adaptation requirements (type of diet and need of nutritional supplementation).

    Measure: Changes in the needs of compensatory treatments in those patients with oropharyngeal dysphagia (nutritional adaptation).

    Time: From April to December 2020. And at 3 and 6 months follow-up.

    Description: Changes in the incidence of hospital readmissions: number of hospital readmissions/patient/6 months.

    Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (incidence of readmissions).

    Time: 3 and 6 months from inclusion.

    Description: Changes in the prevalence: % of patients with hospital readmissions during the follow-up.

    Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (prevalence of readmissions).

    Time: 3 and 6 months from inclusion.

    Description: Incidence: number of visits to the emergency department/patient/ 3 or 6 months.

    Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (number of visits to emergency department).

    Time: 3 and 6 months from inclusion.

    Description: Prevalence: % of patients visiting the emergency department during the follow-up.

    Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (percentage of visits to emergency department).

    Time: 3 and 6 months from inclusion.

    Description: Incidence of respiratory infections (including pneumonia, and COPD exacerbations).

    Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (respiratory complications).

    Time: 3 and 6 months from inclusion.

    Description: 3 and 6 months mortality.

    Measure: Changes in the clinical complications at 3 and 6 months follow up from patient's medical history (mortality).

    Time: 3 and 6 months from inclusion.
    2 Dysphagia in Thoracic Surgical Patients: Incidence, Risk-factors, and Health Related Outcomes

    The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing throacic surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.

    NCT04487028
    Conditions
    1. Thoracic Diseases
    Interventions
    1. Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
    MeSH:Deglutition Disorders Thoracic Diseases
    HPO:Dysphagia Oral-pharyngeal dysphagia

    Primary Outcomes

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

    Measure: Penetration Aspiration Scale

    Time: Baseline

    Secondary Outcomes

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

    Measure: Yale Residue Severity Rating Scale

    Time: Baseline

    Other Outcomes

    Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

    Measure: Vocal Fold Mobility Impairment

    Time: Baseline
    3 Development of a Dysphagia Risk Stratification Tool and Clinical Bedside Screening Tool in Cardiovascular Surgical Patients

    The proposed study seeks to determine the incidence of dysphagia and vocal fold mobility impairment (VFMI) in individuals undergoing cardiovascular surgical procedures. It also seeks to determine the impact of postoperative swallowing impairment on health-related outcomes.

    NCT04496986
    Conditions
    1. Cardiovascular Diseases
    Interventions
    1. Procedure: Fiberoptic Endoscopic Evaluation of Swallowing
    MeSH:Deglutition Disorders Cardiovascular Diseases
    HPO:Abnormality of the cardiovascular system Dysphagia Oral-pharyngeal dysphagia

    Primary Outcomes

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

    Measure: Penetration Aspiration Scale

    Time: Baseline (Prior to surgery)

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of safety to swallowing bolus trials. The development and use of an 8-point, equal-appearing interval scale (8 being best; 1 being worst) to describe penetration and aspiration events are described. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.

    Measure: Penetration Aspiration Scale

    Time: Follow-up - Within 72 hours following extubation from surgery

    Secondary Outcomes

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

    Measure: Yale Residue Severity Rating Scale

    Time: Baseline (Prior to surgery)

    Description: This scale is a validated measure used by trained blinded clinicians to assign ratings of efficiency to swallowing bolus trials. The Yale Pharyngeal Residue Severity Rating Scale was developed, standardized, and validated to provide reliable, anatomically defined, and image-based assessment of post-swallow pharyngeal residue severity as observed during fiberoptic endoscopic evaluation of swallowing (FEES). It is a five-point ordinal rating scale based on residue location (vallecula and pyriform sinus) and amount (none, trace, mild, moderate, and severe).

    Measure: Yale Residue Severity Rating Scale

    Time: Follow-up - Within 72 hours following extubation from surgery

    Other Outcomes

    Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

    Measure: Vocal Fold Mobility Impairment

    Time: Baseline (Prior to surgery)

    Description: During a Fiberoptic Endoscopic Evaluation of Swallowing (FEES), the vocal folds will be visualized using a small camera passed through the open nasal passage. The patient will be asked to make a series of vocal tasks so that we can visualize their movement, any immobility will be notated.

    Measure: Vocal Fold Mobility Impairment

    Time: Follow-up - Within 72 hours following extubation from surgery
    4 Experiences in Dysphagia Management During COVID-19 Pandemic

    The current study is aimed to determine the procedures applied in the dysphagia clinics during the COVID-19 pandemic period. A questionnaire consisting of 30 questions will be implemented. Each participant will be asked to answer the questions.

    NCT04509752
    Conditions
    1. Dysphagia
    2. Covid19
    Interventions
    1. Other: Survey
    MeSH:Deglutition Disorders
    HPO:Dysphagia Oral-pharyngeal dysphagia

    Primary Outcomes

    Description: An online survey will be designed to understand the current clinical conditions and current practice regarding dysphagia management during the pandemic period/normalization period

    Measure: Online survey

    Time: 3 months

    HPO Nodes


    HP:0002015: Dysphagia
    Genes 485
    DNAJC13 LBR NEB FMR1 KCNAB2 GBA ATXN8OS SLC6A9 ADCY6 NEB SACS TBP SYT14 RRM2B TK2 PRPH GNAQ SLC52A3 TYMP CHMP1A MAPT CHD7 PDP1 SNCA ADD3 CLCN1 PCNA CCR6 CHRNA1 GFPT1 VAPB NCAPG2 NR4A2 MEGF10 SLC5A7 VPS13A TGM6 NUP62 ATP1A3 GIGYF2 COLQ HLA-B ATXN3 SCO2 NDUFS2 KMT2A SETBP1 CACNA1G SEMA3E POLG COL13A1 MYMK REEP1 GCH1 STUB1 MECP2 COL7A1 PABPN1 HLA-DQA1 IRF5 TRAPPC12 SDHD DNAJB6 FTL KIAA0319L HGSNAT COQ4 FLCN TPM2 EXOSC9 LRP12 SCARB2 SQSTM1 PLP1 WFS1 LAMA2 ATXN1 MYH8 MAPT DDHD2 SKI GBA VARS1 GEMIN4 AR NECTIN1 SELENON TAF1 KY PUS3 MYO9A MMP1 CNTNAP1 PLEC TBP DGUOK ATXN8OS COLQ FARS2 PFN1 QDPR TUBB4A TAF1 UBQLN2 ND5 CHCHD10 ZFYVE26 NPC1 HLA-DQB1 TBC1D23 C9ORF72 MAPT ALS2 TARDBP MYO9A SCN4A RARS1 PSAP SLC52A2 IRF5 AGRN ACTA1 SNAP25 MYORG MACF1 SLC9A6 CAV1 SNCAIP LRRK2 PRKCG ATP7B RNASEH1 ANKRD11 SPG7 MAP2K2 ATXN2 CHMP2B PYGM DDHD2 CHRNE HLA-DRB1 PLAA NOP56 NEK1 SPG7 ERLIN2 DMPK MSX1 SOD1 DKK1 STXBP1 CARS2 POLG MMP1 SLC25A1 ECM1 COL7A1 SLC19A3 TIMM8A TPM3 RERE DNAJB6 IRF2BPL RRM2B TRAPPC12 POLG PTS LMNB1 KCNK9 ATXN7 ACTA1 RYR1 ASPA FBXO7 PRKRA KIT MFF ATP6 SDHB TRNL1 NDUFS1 KCNC3 TANGO2 ND3 SLC18A3 SPG7 TK2 SNCA TRNW CAV1 CDH1 ND6 SLC52A3 FA2H HPCA NOTCH3 PIGN ASCC1 NDUFAF3 HPRT1 CAVIN1 TIMM8A NGLY1 FTL SPECC1L GDAP2 ALDH18A1 CTNS MAPT MGME1 TPM2 EIF4G1 DLX4 GRHL3 SYT2 LAMB2 DNM1L COL7A1 SLC25A4 SON POLR3A COL7A1 TUBB6 SDHC BRAF OPA1 DCTN1 IRF6 LIFR RRM2B GBA SDHB KIT TRIP4 KLHL7 NEFH CHRNA1 CHCHD10 VAMP1 SCN4A NUP62 ATXN10 NDUFB8 ATXN3 ADH1C SLC1A4 NGLY1 PDGFRA POLG SDHB POLR3A UBTF TOP3A REEP1 SCN4A ERLIN2 SURF1 ATXN8OS IDH2 MAPT FUS PRDM16 PLA2G6 NEUROD2 ATP1A3 MATR3 PANK2 NEB VAC14 GNS SDHC TPM3 SPG11 SLC9A6 GNAO1 RRM2B KLHL41 GALC CHRNE KCNK9 ATXN3 SDHC ND1 ADNP PIK3R5 XRCC1 HTT VAMP1 CHRND CHRND ACOX1 HLA-DRB1 PLEC LINGO1 RHBDF2 NPC2 RERE SQSTM1 YY1 NEB NRXN1 ACTA1 MYOT ADAR TAF1 COQ2 POLR3B KIF5A AFG3L2 ALS2 RNASEH1 MED17 ATP6 CYP27A1 FXN TWNK IKZF1 ATXN8 CYP7B1 POLR3A TTBK2 SPG21 PRKRA CARMIL2 POLG PMP22 ACTA1 DMPK POLG2 GBA2 DGUOK FLAD1 GRM1 VPS35 CHAT GJB1 CDC73 SERPING1 TP63 ATXN3 SYNJ1 REPS1 ATP7A MYOT REV3L UBTF PANK2 NONO CACNA1G GRIN2D MYH7 EPRS1 DLG1 PIGA QDPR ATP1A3 NDUFAF2 ARHGAP29 TANGO2 PANK2 CRYAB TWNK DYSF KIT MATR3 ATN1 SNCA CACNA1A CRLF1 PLXND1 B4GALNT1 YARS2 MAPT PANK2 GBA MID1 KLHL41 LMX1B VAMP1 SCN4A ATXN2 TARDBP POLR3B SLC25A22 TBK1 MECR KBTBD13 ATP13A2 TPM3 TK2 CDC73 TP63 IRX5 NDUFA6 PSEN1 PTS APP PNKD GRHL2 LMOD3 HOXB1 NECTIN1 CACNA1A PRPS1 NDUFS3 NF1 TBK1 KLHL40 MYPN SMC1A KAT6B ASAH1 ALS2 RLIM ACTB GBA PUF60 FRG1 MPZ SPART ITGB4 TUBB4A COL7A1 PRNP VAMP1 NOS1 ARX NOP56 ATXN8 C19ORF12 EBF3 SPG21 IDH1 NDUFA9 ND4 FBXL4 CNTNAP2 KLHL40 GUCY1A1 CCN2 CHAT OPTN UBB SLC5A7 TRNK BMP4 LMNB1 GABRD TBCD SETX FERMT1 MSX1 ND2 VCP AFG3L2 PEX16 POLG ATXN7 STUB1 ACTA1 GMPPA SDHA ACTG2 TRNV DAB1 PYROXD1 ATXN1 C12ORF65 CCR6 SIK1 RAI1 PDE8B TPM3 SCN3A PLA2G6 ALS2 KCND3 KLHL41 CCN2 ERLIN2 PLAA IRF6 SYT14 SETX GLUD2
    Protein Mutations 1
    V158M
    SNP 0

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002015: Dysphagia
    Genes 485
    DNAJC13 LBR NEB FMR1 KCNAB2 GBA ATXN8OS SLC6A9 ADCY6 NEB SACS TBP SYT14 RRM2B TK2 PRPH GNAQ SLC52A3 TYMP CHMP1A MAPT CHD7 PDP1 SNCA ADD3 CLCN1 PCNA CCR6 CHRNA1 GFPT1 VAPB NCAPG2 NR4A2 MEGF10 SLC5A7 VPS13A TGM6 NUP62 ATP1A3 GIGYF2 COLQ HLA-B ATXN3 SCO2 NDUFS2 KMT2A SETBP1 CACNA1G SEMA3E POLG COL13A1 MYMK REEP1 GCH1 STUB1 MECP2 COL7A1 PABPN1 HLA-DQA1 IRF5 TRAPPC12 SDHD DNAJB6 FTL KIAA0319L HGSNAT COQ4 FLCN TPM2 EXOSC9 LRP12 SCARB2 SQSTM1 PLP1 WFS1 LAMA2 ATXN1 MYH8 MAPT DDHD2 SKI GBA VARS1 GEMIN4 AR NECTIN1 SELENON TAF1 KY PUS3 MYO9A MMP1 CNTNAP1 PLEC TBP DGUOK ATXN8OS COLQ FARS2 PFN1 QDPR TUBB4A TAF1 UBQLN2 ND5 CHCHD10 ZFYVE26 NPC1 HLA-DQB1 TBC1D23 C9ORF72 MAPT ALS2 TARDBP MYO9A SCN4A RARS1 PSAP SLC52A2 IRF5 AGRN ACTA1 SNAP25 MYORG MACF1 SLC9A6 CAV1 SNCAIP LRRK2 PRKCG ATP7B RNASEH1 ANKRD11 SPG7 MAP2K2 ATXN2 CHMP2B PYGM DDHD2 CHRNE HLA-DRB1 PLAA NOP56 NEK1 SPG7 ERLIN2 DMPK MSX1 SOD1 DKK1 STXBP1 CARS2 POLG MMP1 SLC25A1 ECM1 COL7A1 SLC19A3 TIMM8A TPM3 RERE DNAJB6 IRF2BPL RRM2B TRAPPC12 POLG PTS LMNB1 KCNK9 ATXN7 ACTA1 RYR1 ASPA FBXO7 PRKRA KIT MFF ATP6 SDHB TRNL1 NDUFS1 KCNC3 TANGO2 ND3 SLC18A3 SPG7 TK2 SNCA TRNW CAV1 CDH1 ND6 SLC52A3 FA2H HPCA NOTCH3 PIGN ASCC1 NDUFAF3 HPRT1 CAVIN1 TIMM8A NGLY1 FTL SPECC1L GDAP2 ALDH18A1 CTNS MAPT MGME1 TPM2 EIF4G1 DLX4 GRHL3 SYT2 LAMB2 DNM1L COL7A1 SLC25A4 SON POLR3A COL7A1 TUBB6 SDHC BRAF OPA1 DCTN1 IRF6 LIFR RRM2B GBA SDHB KIT TRIP4 KLHL7 NEFH CHRNA1 CHCHD10 VAMP1 SCN4A NUP62 ATXN10 NDUFB8 ATXN3 ADH1C SLC1A4 NGLY1 PDGFRA POLG SDHB POLR3A UBTF TOP3A REEP1 SCN4A ERLIN2 SURF1 ATXN8OS IDH2 MAPT FUS PRDM16 PLA2G6 NEUROD2 ATP1A3 MATR3 PANK2 NEB VAC14 GNS SDHC TPM3 SPG11 SLC9A6 GNAO1 RRM2B KLHL41 GALC CHRNE KCNK9 ATXN3 SDHC ND1 ADNP PIK3R5 XRCC1 HTT VAMP1 CHRND CHRND ACOX1 HLA-DRB1 PLEC LINGO1 RHBDF2 NPC2 RERE SQSTM1 YY1 NEB NRXN1 ACTA1 MYOT ADAR TAF1 COQ2 POLR3B KIF5A AFG3L2 ALS2 RNASEH1 MED17 ATP6 CYP27A1 FXN TWNK IKZF1 ATXN8 CYP7B1 POLR3A TTBK2 SPG21 PRKRA CARMIL2 POLG PMP22 ACTA1 DMPK POLG2 GBA2 DGUOK FLAD1 GRM1 VPS35 CHAT GJB1 CDC73 SERPING1 TP63 ATXN3 SYNJ1 REPS1 ATP7A MYOT REV3L UBTF PANK2 NONO CACNA1G GRIN2D MYH7 EPRS1 DLG1 PIGA QDPR ATP1A3 NDUFAF2 ARHGAP29 TANGO2 PANK2 CRYAB TWNK DYSF KIT MATR3 ATN1 SNCA CACNA1A CRLF1 PLXND1 B4GALNT1 YARS2 MAPT PANK2 GBA MID1 KLHL41 LMX1B VAMP1 SCN4A ATXN2 TARDBP POLR3B SLC25A22 TBK1 MECR KBTBD13 ATP13A2 TPM3 TK2 CDC73 TP63 IRX5 NDUFA6 PSEN1 PTS APP PNKD GRHL2 LMOD3 HOXB1 NECTIN1 CACNA1A PRPS1 NDUFS3 NF1 TBK1 KLHL40 MYPN SMC1A KAT6B ASAH1 ALS2 RLIM ACTB GBA PUF60 FRG1 MPZ SPART ITGB4 TUBB4A COL7A1 PRNP VAMP1 NOS1 ARX NOP56 ATXN8 C19ORF12 EBF3 SPG21 IDH1 NDUFA9 ND4 FBXL4 CNTNAP2 KLHL40 GUCY1A1 CCN2 CHAT OPTN UBB SLC5A7 TRNK BMP4 LMNB1 GABRD TBCD SETX FERMT1 MSX1 ND2 VCP AFG3L2 PEX16 POLG ATXN7 STUB1 ACTA1 GMPPA SDHA ACTG2 TRNV DAB1 PYROXD1 ATXN1 C12ORF65 CCR6 SIK1 RAI1 PDE8B TPM3 SCN3A PLA2G6 ALS2 KCND3 KLHL41 CCN2 ERLIN2 PLAA IRF6 SYT14 SETX GLUD2
    Protein Mutations 1
    V158M
    SNP 0

    Reports

    Data processed on September 26, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,180 reports on interventions/drugs

    MeSH

    691 reports on MeSH terms

    HPO

    263 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook